Eudocia Quant Lee

Dana-Farber Cancer Institute is a world-renowned treatment and research center dedicated to providing expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of the disease. As a principal teaching affiliate of Harvard Medical School, it leads numerous clinical trials and research initiatives, particularly in neuro-oncology through its Center for Neuro-Oncology. The institute is a pioneer in adaptive platform trials, such as the INSIGhT trial, which utilizes Bayesian adaptive randomization to efficiently test multiple experimental therapies for glioblastoma. Dana-Farber's research spans diverse modalities including targeted molecular therapies, immunotherapies, and oncolytic viruses, often in collaboration with major pharmaceutical partners.